Stay updated on Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the effects of new drugs on ovarian cancer, specifically focusing on platinum resistant high grade serous ovarian cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:36.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, the inclusion criteria now specify that the study will enroll women with platinum-resistant high-grade serous ovarian cancer and is open to minorities, but not designed to measure differences in intervention effects.
    Difference
    53%
    Check dated 2024-05-22T21:11:03.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:14:22.000Z thumbnail image

Stay in the know with updates to Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.